ArticleMolecular neurobiology2026
Up-regulation of miR-548 m Leading to Neuroinflammation to Promote the Progression of Alzheimer's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation mediated by microglia is recognized as a critical contributor to Alzheimer's disease (AD) pathogenesis, and P2RY12 maintains microglial homeostasis. MicroRNAs regulate gene expression post-transcriptionally and have been implicated in modulating microglial activation states during AD by affecting inflammatory pathways. This study aimed to investigate the role of miR-548 m in regulating microglial polarization and neuroinflammation in Alzheimer's disease. Male APP/PS1 transgenic and wild-type mice were utilized as animal models alongside cultured microglial cells for in vitro studies. Behavioral assessments, including contextual fear Morris water maze (MWM) and fear conditioning (FC), evaluated cognitive function. Molecular analyses comprised RT-qPCR western blot, and ELISA, as well as dual-luciferase reporter assays to validate miR-548 m and P2RY12 interactions. In vivo modulation of miR-548 m expression was achieved via stereotaxic intracerebral injections of agomir or antagomir oligonucleotides targeting the dentate gyrus. MiR-548 m was significantly upregulated in AD. Overexpression of miR-548 m promoted microglial M1 polarization characterized by increased pro-inflammatory cytokines (TNF-α, IL-6, iNOS, IL-1β) and reduction in M2 anti-inflammatory markers (Arg1, CD206, IL-4, TGF-β). Inhibition of miR-548 m improved spatial learning and memory performance while attenuating microglial activation in vivo. Luciferase reporter assays confirmed that P2RY12 is a direct downstream target suppressed by miR-548 m. And overexpression of miR‑548 m reversed the inflammatory effects induced by P2RY12 overexpression. These findings demonstrate that elevated miR‑548 m exacerbates neuroinflammation through negative regulation of P2RY12 expression, leading to enhanced microglial M1 polarization during AD progression. Targeting the miR‑548 m/P2RY12 axis may provide a novel therapeutic for mitigating AD.
Indexed as
Identifiers
41968260What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.